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1. Introduction 
Lung microangiopathy is a little known negative influence of diabetes mellitus on the 
functioning of the lungs. In current medical practice lung microangiopathy is diagnosed by 
comparing two measurements of lung diffusing capacity – one with the subject standing 
and one with the subject lying. The necessity to take two measurements is inconvenient.  
In lung microangiopathy we observe a reduction of diffusing capacity, lung flow and 
volume. Diabetes is a chronic illness that can lead to diabetic angiopathy, a pathology of the 
blood vessels (arteries, veins and capillaries). There are two types of diabetic angiopathy: 
macroangiopathy (disease of the larger blood vessels) and microangiopathy (microvascular 
pathology). The examples of angiopathy include: neuropathy, nephropathy and retinopathy.  
Current knowledge regarding diabetic lung microangiopathy is limited. Histopathological 
examination of lung biopsy samples is not a conclusive test of the consequences of diabetes 
(Dalquen, 1999). Animal experiments and post-mortem examinations have disclosed the 
influence of diabetes on the lung capillaries and alveolar-capillary membranes (Kida et al, 
1993), (Kodolova et al, 1982) and (Popov& Simionescu, 1997). Histopathological tests have 
revealed the thickening of the alveolar and venous capillary walls (Matsubara& Hara, 1991) 
and (Weynand et al, 1999).  
Lung diffusing capacity measurements illustrate the state of alveolar-capillary barrier 
(Goldman, 2003). These are measurements of diffusion across the alveolar-capillary 
membrane. For diagnosing microangiopathy, the lung diffusing capacity is measured in two 
body positions: standing ( standingLD ) and lying on the back (
lying
LD ), (Strojek et al, 1993) and 
(Kuziemski et al, 2008). On account of the human anatomic structure, diffusing capacity 
depends on the body’s position. For healthy subjects the diffusing capacity increases in the 
reclined position, lying standingL LD D . The opposite is observed in the case of microangiopathic 
patients: the diffusing capacity decreases when the subject is lying lying standingL LD D . This is 
the result of blood vessel damage and alveolar thickening caused by diabetes (Kuziemski et 
al, 2009). Only the fact that diffusing capacity increases or decreases in a given position is 
important as far as microangiopathy diagnosis is concerned. 
Spirometry (measurement of the volume and flow of inhaled and exhaled air) is the most 
common pulmonary function test. It is helpful in diagnosing asthma, pulmonary fibrosis, 
cystic fibrosis, and COPD (Chronic Obstructive Pulmonary Disease). 
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Research (Goldman, 2003), (Kaminski, 2004) has shown that a single spirometry test does 
not provide sufficient information for a diagnosis of lung flow limitation and lung volume 
reduction caused by diabetes mellitus. Instead we need long-term observations of 
spirometry results to diagnose lung microangiopathy. Microangiopathy lung impairment is 
characterised by a decrease in spirometric parameters FVC  (the maximum volume of air 
that can be exhaled or inspired during a forced manoeuvre) and 1FEV  (the forced 
expiratory volume during the first second of expiration) (Davis et al, 2004), (Litonjua et al, 
2005), (Yeh et al, 2008). 
A later study (Kuziemski et al, 2009) proved that a single spirometric test is insufficient to 
identify lung microangiopathy on account of functional reserve breathing. The reserves 
compensate, to some extent, the lung dysfunction, and thus the negative effect of diabetes is 
concealed until the effect reaches a higher level of impairment.  
Since the direct measurements of pulmonary function are not conclusive and post-mortem 
autopsies do not serve the given patient, the diagnostics have to be based on such indirect 
results as spirometric measurements and modelling. It is probably also capable of revealing 
lung microangiopathy if the results are very carefully analysed. 
Perfusion computed tomography (pCT) is a diagnostic method that enables the imaging of 
the organ and tissue. This is a powerful tool for diagnosing perfusion of internal organs 
such as the brain, liver, pancreas, spleen, kidneys and lungs (Alonzi & Hoskin, 2006), 
(Blomley et al, 1993), (Cao, 2011), (Eichinger et al, 2010), (Kuziemski et al, 2011). The method 
enables quantitative evaluation of circulation by determining changes in tissue during the 
flow of a contrast agent in the blood vessels. Changes, when compared to a normal tissue, 
can indicate tissue pathology. Lung pCT measurements can help in the diagnosis of cystic 
fibrosis (Eichinger et al, 2010) and diabetes (Kuziemski et al, 2011). It can also help to 
differentiate benign pulmonary nodules from lung cancer (Alonsi & Hoskin, 2006). 
The technique of lung pCT involves the intravenous injection of a non-iodinated contrast 
agent and the sequential scanning of the diagnosed region of the chest. There are a number 
of pulmonary perfusion parameters, calculated pixel by pixel on the basis of raw CT data, 
which are next analysed in order to reveal differences between the normal and altered 
tissue. The most useful perfusion parameters are: blood volume (BV), blood flow (BF), mean 
transit time (MTT), time to peak (TTP) and permeability surface (PS) (Kuziemski et al, 2011). 
The diagnosis of pulmonary function has to be based on indirect results, such as diffusing 
capacity, spirometry and pCT because direct assessment is difficult.  
2. Materials 
The tests were performed on a group of 72 diabetics. People with cardiovascular disease and 
smokers were not included in this group.  
First the diabetics were tested for microangiopathy, by comparing diffusing capacity in 
standing and lying position, and on this basis they were split into two groups: 44angiopM   
and 28non angiopM   , with and without microangiopathy respectively.  
The spirometric tests were carried out on all the patients ( n-angiop no angiopM M M  ) to obtain 
the following spirometric parameters: 1FEV  (forced expiratory volume during the first 
second of expiration), FVC  (the maximum volume of air that can be exhaled or inspired 
during a forced manoeuvre), PEF  (peak expiratory flow), 50MEF  (maximal instantaneous 
forced expiratory flow where 50% of the FVC  remains to be expired), 75/25MEF  (maximal 
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mid-expiratory flow), IC  (inspiratory capacity) and 1%FEV FVC  (percentage relation of 
1FEV  to FVC ).  
The pCT test was performed on a group of 18 subjects: 10 diabetics and 8 non-diabetic 
volunteers. The local perfusion parameters BF  (blood flow), BV (blood volume), MTT  
(mean transit time) and PS  (permeability surface) were obtained in selected regions of 
interest (ROI) in the artery and parenchyma.  
The patients classified as suffering from microangiopathy had breathing impairment 
symptoms cause only by diabetes. They were all non-smokers and had not been diagnosed 
with any other acute or chronic respiratory disease.  
3. Diffusing capacity 
The quality of gas exchange in the lungs depends on the diffusing capacity 1[ ]LD mol s kPa
  . 
During the measurement of LD  (American Thoracic Society, 1995) a person takes a full 
inhalation of air mixed with small amounts of carbon monoxide and helium. The mixture is 
held in the lungs for a few seconds and then exhaled. The first part of the expired gas is 
discarded. The next portion, which includes gas from the alveoli, is collected. The LD  is 
determined by analyzing and comparing the concentrations of carbon monoxide and helium 
in the samples of the inhaled gas and the exhaled gas. The alveolar volume AV  is also 
determined in this test by using the single-breath helium dilution technique.  
3.1 The oxygen pathway model 
Fig. 1 shows oxygen diffusion. Oxygen transportation from the alveoli to erythrocytes, 
through the alveoli-capillary barrier, is presented as the flow 121  [ ]
-f g s . The blood 
saturation (0,1)S , (also given as (0,100%)S ) shows what part (percentage) of oxygen 
capacity (maximum amount of oxygen transported by the erythrocytes) is currently being 
transported in the blood. Poorly oxygenated blood enters the pulmonary artery and then, 
enriched in oxygen, flows out of the lung through the pulmonary vein. Lung arterial blood 
saturation AS  differs from lung venous blood saturation VS , A VS S . 
Flows 120[ ]f g s
  and 102[ ]f g s  represent the amount of oxygen in the blood flowing into 
the lung and flowing out of the lung. The oxygen diffusion model is: 
 
       
         1 21 12 21 20 02 2
, 0
, 0
m t f t u t m
m t f t f t f t m
      

  (1) 
where the 1( )[ ]m t g  and 2( )[ ]m t g  are the 2O  masses in the alveoli and in the blood vessels 
respectively. The initial states 1(0)[ ]m g  and 2(0)[ ]m g  depend on oxygen partial pressure 
1(0) 13.32 [k ]P Pa , 2(0) 12.63 [ ]P kPa  and region volume 1 AV V , 4 32 10 [ ]V m , 
(Dalquen, 1999) ,West, 2008) and (Taylor et al, 1989). The alveolar volume 1 AV V  is 
measured during the diffusing capacity test. The relationship between the 2O  mass and the 
pressure is: 
2
( ) ( )i i O iP t RTm t M V , 1,2i  , where 1 1 [ ]- -R N m K  mol  is gas constant,  T  is 
absolute temperature and 
2
1[  ]OM g mol
  is the molecular mass. The mass diffusion, i.e. flow 
21( )f t  via the membrane is caused by the concentration gradient 1 2 0c c c    , where 
( ) ( )i i ic t m t V , 1,2i  : 
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Fig. 1. The passage of oxygen from the airways to the lung vessels. The diffusing capacity 
LD  describes the condition of the alveoli-capillary barrier. The oxygen is bound in reversible 
bonds 8[ ]HbO with the haemoglobin in the lung vessels 
 1 221
1 2
( ) ( )
( ) L
m t m t
f t D R T
V V
       
 (2) 
The signal ( )u t  represents respiratory flow with the period pT , the delay time 0  [s]t  (the 
time the air passes through the airway to the alveoli) and the duty cycle d . The input 
amplitude 1[  ]g s  depends on the organism’s metabolic rate ( MR ), i.e. the organism’s need 
for oxygen.  
In medical practice, blood saturation S  gives the basic information concerning the quantity 
of oxygen transported from the lungs to all the other organs. The kinetics of oxygen 
association with haemoglobin is described in Hill’s equation (Khee-Shing, 2007): 
       
2
21
n
V n
K P t
S t
K P t

 
 (3) 
where 2( )P t  is oxygen partial pressure in the blood, 2.8n   is the Hill’s constant and 
101.2256 10  [1 ( ) ]nK Pa   is the association constant. The relationship between the 
endogenous inflow 20f  , the outflow 02f  and the organism’s need for oxygen MR  is as 
follows: 
 20 02( ) ( )f t f t MR   (4) 
www.intechopen.com
 Novel Methods for Diagnosis of Pulmonary Microangiopathy in Diabetes Mellitus 
 
607 
while the outflow 02f  depends on the blood velocity 
3 1[ ]m s  , maximum erythrocyte 
oxygen capacity 3[ ]mol m   and venous blood saturation ( )VS t  
    
202 V O
f t S t M     (5) 
The elimination flow 02f , according to Hill’s equation, is: 
    
2
2
02 2
2
,
1
n
nHill
O Hill
Hill O
c R T
f t M c K m t
c M V
             
 (6) 
Taking into account (4), (5) and (6), the oxygen diffusion model is: 
 
         
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where       1 0 0
0
p p p
i
MR
u t i T t i T t T d
d


            1 1 . 
The model parameters 1 1Lp D R T V    and 2 2Lp D R T V    can be estimated with the use 
of measurements 1,LD V  and physiological constants 2, ,R T V . 
The example measurements (lying body position),  3 35.42 10 [ ]non angiopAV m
   , 
 7 11.54 10 [ ]non angiopLD mol s Pa
     , 3 35.71 10 [ ]angiopAV m   and 
7 11.59 10 [ ]angiopLD mol s Pa
     together with the constants: 3 32 0.10 10  [ ]V m   (blood 
volume in lung capillary vessels), 293 [ ]T K  (absolute temperature) and 
1 18.314 [ ]R N m mol K     (gas constant), allow calculation of the example model parameter 
estimates:  
2
1 2
2
1 2
[ , ] [5.6315 10 ,  3.3271]
[ , ] [6.2128 10 ,  3.9621]
angiop angiopangiop
non angiop non angiopnon angiop
p p
p p

  
  
  
p
p
 
The model parameter estimates have been calculated for all the 72M   patients. 
3.2 Statistical comparison of measurement and modelling results for 
microangiopathic and non- microangiopathic patients 
Measurements were made for two groups of diabetic patients: ones with diagnosed 
microangiopathy and others with no microangiopathy. Lung microangiopathy was 
identified when standing lyingL LD D . This examination also gives the alveoli volume 1AV V .  
The null hypothesis 0H  assumes that the mean values in both groups of patients are the 
same. Calculated ex post significance level p  is compared with ex ante significance level   
(test-T). If a test of statistical significance gives ex post significance level p , which is lower 
than the  , the null hypothesis is rejected, alternatively we no grounds to reject this 
hypothesis. Table 1 and Table 2 show a statistical comparison of spirometry measurements 
and model parameters obtained from microangiopathic and non-microangiopathic patients. 
The results presented in Table 1 ( lying lying  0 :  
angiop non angiop
L LH D D
 is rejected and the 
conclusion is: lying lying  angiop non angiopL LD D
 ) suggest the possibility of diagnosing 
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microangiopathy on the basis of lyingLD  only, instead of 
lying
LD  and 
standing
LD . The lack of 
statistical significance for standingLD  means that it is not useful as an individual value for 
microangiopathy diagnosis. 
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 
level p  Mean value 
Standard 
deviation 
Mean value 
Standard 
deviation 
standing
LD  1.64 10
-7 0.14 10-7 1.48 10-7 0.11 10-7 0.05p   
standing
AV  5.95 10
-3 0.21 10-3 5.65 10-3 0.21 10-3 0.05p   
lying
LD  1.35 10
-7 0.06 10-7 1.63 10-7 0.14 10-7 0.05p   
lying
AV  6.04 10
-3 0.27 10-3 5.90 10-3 0.40 10-3 0.05p   
Table 1. Statistical comparison of LD  and AV . For 
lying
LD  ex post significance level is p  , 
0.05  . The null hypothesis lying lying  0 :  angiop non angiopL LH D D   concerning equality of mean 
diffusing capacity values in both groups was rejected. lyingLD  allows us to distinguish 
between patients with and without microangiopathy, while the rest do not.   
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 
level p  Mean value 
Standard 
deviation 
Mean value 
Standard 
deviation 
Measurements taken in standing body position 
1p  26.6176 10  20.4720 10  26.1900 10  20.2792 10  0.05p   
2p  3.9330 0.3447 3.5301 0.2730 0.05p   
Measurements taken in lying body position 
1p  5.4339 10-2 0.2233 10-2 6.5672 10-2 0.3139 10-2 0.01p   
2p  3.2427 0.1551 4.0981 0.3518 0.01p   
Table 2. Statistical comparison of 1p  and 2p . In the lying body position the ex post 
significance level  is p  , 0.01   and the 0H , concerning the equality of mean 
parameter values, is rejected. These parameters allow for a distinction to be made between 
patients with and without microangiopathy. 
Next, the null hypothesis 0
angiop non angiop
i iH p p
  , 1,2i   was tested (Table 2). The 
Kolmogorov-Smirnov test accepted the normality hypothesis concerning 1p  and 2p  at the 
significance level of 0.01p  . Therefore the mean values and standard deviations were 
calculated and the null hypothesis 0
angiop non angiop
i iH p p
   was tested.  
For 1p  and 2p , in lying body position, the ex post significance level p  , 0.01   and so 
the 0H  was rejected. These parameters enable a distinction to be made between patients 
with and without microangiopathy.  
In a standing body position ( 0.05p  ) the parameters 1p  and 2p  are not useful for 
microangiopathy diagnosis.  
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The results in Table 1 and Table 2 indicate the possibility of using a diagnostic test based on 
a single measurement lyingLD , and also on the basis of modelling results 1p .and 2p . 
3.3 Binary classification on the basis of diffusing capacity measurement and 
modelling 
Statistical analyses show that a single measurement lyingLD  and the model parameters 1p , 
2p  contain information concerning lung microangiopathy. The question remains as to 
whether or not such values can be used for binary classification. Binary classification is the 
classifying of the members of mixed group -angiop non angiopM M M   into two subgroups, 
angiopM  and non angiopM  , on the basis of whether or not they have microangiopathy. For this 
purpose an appropriate classification algorithm has to be chosen. 
To select the best potential classification algorithm, statistical measures, sensitivity and 
specificity (Panzer, Blach & Griner, 1991) were considered. Sensitivity Sens  is the ability of a 
test to detect a disease when it is really present. Specificity Spec  is the ability to confirm the 
absence of a disease in patients when it is really absent. 
 
 
  
True Positive
Sens
True Positive False Negative
   (8) 
 
 
  
True Negative
Spec
True Negative False Positive
   (9) 
The theoretically optimal prediction is: 100%Sens   ( all the sick patients were identified as 
sick) and  100%Spec   (none of the healthy patients was identified as sick).  
 
 
Fig. 2. Classification algorithms based on 1p  and 2p ; I) 2pM  are classified as 
microangiopathic and 
2p
M M  are classified as non-microangiopathic, II) 
1 2p p
M M  are 
classified as microangiopathic and 
1 2
( )p pM M M   are classified as non-microangiopathic 
For binary classification the discrimination levels (boundaries, diagnostic thresholds) 
LD
H , 
1p
H  and 
2p
H  have to be calculated, respectively for LD , 1p  and 2p . The discrimination 
levels classify the test result as positive or as negative. The parameter value where 
maxSens Spec   was chosen as the parameter’s diagnostic threshold. 
Among different classification algorithms using 1p , 2p , 1pH  and 2pH  the best are the two 
shown in Fig. 2.  
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Classification 
algorithm 
Wide range of anthropometric 
features, 72M   (men and 
women, 21-69 y, 1.50-1.95m) 
Narrowed range of 
anthropometric features 
1 22M  (women, over 50 y, 
under 1.65 m) 
[%]Sens  [%]Spec  [%]Sens  [%]Spec  
I. 1 2,p p  50 84 62 87 
II. 2 1,p p  76 50 79 80 
lying
LD  33 61 62 71 
Table 3. Classification results obtained for entire group of 72M   subjects and for the group 
of 1 22M   women, over 50 y, under 1.65 m. The best results are underlined.  
Therefore the diagnostic procedure shown in Fig. 3 is recommend. 
 
 
Fig. 3. Diagnostic procedure with the use of lyingLD , 
lying
AV  measurements, constants R, T, 
2V  and calculated 1 2,  p p , 1pH  and 2pH . For binary classification the more conclusive 
algorithms I) (with respect to Spec ) and II) (with respect to Sens ) are recommended. 
The binary classification was performed for the 72M   subjects. The results were compared 
with already known medical diagnoses of 44 microangiopathic patients and 18 patients with 
no microangiopathy. Then the sensitivity and the specificity were calculated according to 
equations (8) and (9), (Table 3). The larger the Sens  and Spec , the better. It seems 
reasonable to assume that results larger than 75% are satisfactory. Therefore an algorithm 
should be selected to fulfil this requirement, and not every entry in Table 3 does. 
Diagnostic thresholds, calculated on the basis of 72M   measurement data, are: 
1
25.80 10pH
  , 
2
3.50pH   and -71.57 10LDH   . The best statistical measures obtained 
are: 76%Sens   (algorithm II) and 84%Spec   (algorithm I). The results for lyingLD , 
33%Sens   and 61%Spec  , are less than 75% and quite inadequate. 
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The thresholds established as common for the entire group did no take into account such 
important factors as age, height and gender. Therefore a subgroup 1 22M   was selected 
(women, over 50 years old and less than 1.65 m tall). Then the new diagnostic thresholds 
1
25.42 10pH
  , 
2
3.06pH  , -71.30 10LDH    and new Sens  and Spec  were calculated. As 
expected, both the new Sens  and Spec  were noticeably larger.  
The diagnostic procedure in Fig. 3 uses lyingLD  and 
lying
AV measurements, and R , T  and 2V  
physiological constants to calculate the 1p  and 2p  in a patient. Then algorithm I (with the 
most conclusive Sens ) and algorithm II (with the most conclusive Spec ) are applied 
together with 
1p
H  and 
2p
H  diagnostic thresholds to obtain a binary classification result.  
This procedure produces one of two possible results: 1) high probability of lung 
microangiopathy or 2) high probability of no lung microangiopathy. This can serve as useful 
confirmation in a doctor’s diagnosis.  
The final decision is made by the doctor conducting the diagnosis, who can take into 
account this classification result along with other diagnostic data. 
4. Spirometry 
The most popular spirometry method is a dynamic one. The pneumotachometer (Miller, 
Harkinson&Brusasco, 2005) defines the volume ( ) [ ]V t l  and airflow 1( )[ ]Q t ls  during the 
inhalation and exhalation. The flow-volume curve ( )Q V  is received on the basis of the 
spirometry measurements of ( )V t  and ( )Q t . Specific ventilation manoeuvres are required 
in the spirometric test. The measurement is preceded by a period of quiet breathing–in and 
out (Fry, Hyatt, 1960). Next the maximal breath–in and the maximal forced breath–out 
manoeuvres are performed as the important parts of the spirometric test. 
The respiration parameters are defined on the basis of the volume–time curve ( )V t  and the 
flow–volume curves ( )Q V  (see Fig. 4 and Fig. 5), (Miller, Harkinson&Brusasco, 2005).  
In medical practice two terms, volume and capacity, are used. The difference between them 
is based on the assumption that volume refers to lung volumes, while capacity refers to 
different combinations of lung volumes, usually in relation to inhalation and exhalation.  
The relations between volumes and capacities are presented in equations (10). 
 
TLC VC RV
TLC IC FRC
 
   (10) 
The following respiratory parameters have been defined:  [ ]TLC l  (Total Lung Capacity) is 
the volume of air in the lungs at the end of maximal inhalation;  [ ]VC l  (Vital Capacity) is 
the maximum volume of air that can be exhaled or inhaled during either a forced ( FVC ) or 
a slow (VC ) manoeuvre;  [ ]RV l  (Residual Volume) is the volume of air remaining in the 
lungs after the maximal exhalation;  [ ]IC l  (Inspiratory Capacity) is the maximal volume of 
air that can be inhaled from the resting expiratory level;  [ ]FRC l  (Functional Residual 
Capacity) is the volume of air in the lungs at the resting end-expiration.  
Also defined are the following respiratory parameters: 1  [ ]FEV l  the forced expiratory 
volume during the first second of expiration;   FET s  the forced expiratory time;  [ ]FIT s  
the forced inspiratory time; 1 [  ]PEF l s  (Peak Expiratory Flow) and 1 [  ]PIF l s  (Peak 
Inspiratory Flow) are respectively the maximal expiratory and the maximal inspiratory flow  
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Fig. 4. The spirometry parameters defined on the basis of volume-time curve  V t . 
 
 
Fig. 5. The spirometric parameters defined on the basis of flow–volume curve  Q V . 
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rates achieved;   TPEF s  the time of maximal expiratory flow; 175 50 25, ,  [ ]-MEF MEF MEF l s  
maximal instantaneous forced expiratory flow where 75, 50, 25% of the FVC  remains to be 
expired; 175/25  [ ]
-MEF l s  is the maximal mid-expiratory flow and 1%FEV FVC  is the 
percentage relation of 1FEV  to FVC . 
The European Respiratory Society (Miller, Harkinson & Brusasco, 2005) has published the 
spirometric norms and the reference values for these spirometric parameters. The reference 
values of the respiration parameters, obtained for a representative healthy population, are 
used for the interpreting the spirometry data and making the diagnosis. The reference 
values depend on the patient’s anthropometric data, such as age, height and gender. In 
some medical cases (asthma, pulmonary fibrosis, cystic fibrosis and COPD) the spirometric 
parameter boundary values have already been defined. However, as far as lung 
microangiopathy is concerned, this has not yet been done.  
According to medical practice experience, lung microangiopathy is diagnosed on the basis 
of the following spirometric parameters: 1FEV , FVC , PEF , 50MEF , 75/25MEF , IC  and 
1%FEV FVC . These spirometric parameters were collected from the 72M   diabetic patients.  
However, a single spirometric test is not sufficient to diagnose the lung flow and volume 
reduction caused by microangiopathy; long term observation is necessary. Therefore one 
should consider an alternative method. By using the spirometric results in a statistical 
significance test, we can find the spirometric parameters that are most responsive to lung 
microangiopathy.  
4.1 Spirometric parameters. Statistical comparison of results for microangiopathic 
and non- microangiopathic patients 
Traditional spirometric parameters were tested for their ability to detect lung 
microangiopathy. The mean, standard deviation and the statistical significance level p  for 
spirometric parameters are presented in Table 4.  
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 
level p  
Mean 
spirometry 
parameter 
Standard 
deviation 
Mean 
spirometry 
parameter 
Standard 
deviation 
1FEV  2.970 0.699 2.919 0.832 0.05p   
FVC  4.245 0.911 4.015 1.245 0.05p   
PEF  9.175 1.545 11.621 1.914 0.05p   
50MEF  5.258 1.384 3.691 1.637 0.05p   
25/75MEF  2.896 1.051 2.853 1.206 0.05p   
IC  3.182 0.706 3.275 1.097 0.05p   
1%FEV FVC  70.731 7.482 73.621 8.880 0.05p   
Table 4. Statistical comparison of spirometric parameters for microangiopathic and non-
microangiopathic patients. In every case the ex post significance level p  , 0.05  , which 
means that 0H  concerning mean parameter value equality is not rejected. The parameters 
do not allow for a distinction to be made between patients with and without 
microangiopathy.  
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The parameters do not show statistical significance in detecting microangiopathy: ex post 
significance level p  is larger than ex ante significance level 0.05  , which confirms the 
null hypothesis concerning equality of mean values for both groups. Therefore, none of 
spirometric parameters are useful in diagnosing microangiopathy. 
4.2 Spirometry modelling 
The maximal breathing-in flow was modelled by means of the sine function. The forced 
breathing-out flow was finally mimicked using the gamma variate function (Askey R.A.& 
Roy R,2007) – after testing a large group of prospective regression functions, such as 
exponentials, polynomials, etc (Kalicka et al, 2007).  
The maximal inflow ( )inQ V  is modelled as follows: 
  ( ) sin ,  0in inQ V A V V FVC      (11) 
where 1 [  ]inA l s
  and 1 [ ]l   are model parameters and FVC  is the forced vital capacity.  
For modelling ( )outQ V  during the maximal outflow, the following gamma variate function 
is implemented: 
     ,  0b V aoutQ V K V e FVC V     (12) 
where 1[  ]K l s , b  and 1 [ ]a l  are model parameters. 
The model consists of the equations (11) and (12). The model parameters are arranged into 
vector [ ] [ , , , , ]i inp A K b a p ,  1 5i   . The parameter estimates were obtained using the 
least square procedure, according to the following: 
     max 2model meas meas
0
arg min , ,
V
V
Q V Q V

     

p
p p y  (13) 
where meas meas 1 50 25/50[ ] [ , , , , , , % ]; 1 7jy FEV FVC PEF MEF MEF IC FEV FVC j   y  is vector 
of measurements and maxV FVC . The fitting procedure was executed separately to obtain 
,  inA   and ,  ,  K b a  based on the equations (11) and (12) respectively. 
The parameter vector [ , , , , ] [3.780 1.030 20.580 0.772 1.507]inA K b a , , , ,  p  is an example of 
the model identification results. This was obtained from a 59-year-old woman suffering 
from lung microangiopathy. The spirometric parameters obtained from the patient were: 
1 2.25FEV  , 2.84FVC  , 5.79PEF l s , 50 3.47MEF l s , 75/25 2.63MEF l s , 2.81IC   
and 1% 78.95%FEV FVC  . 
Calculations of [ , , , , ]inA K b ap  were performed for 72M   diabetic patients. Fig. 6 
shows an example of the model regression functions ( )inQ V  and ( )outQ V  drawn for the 
[ , , , , ]inA K b a p [3.780 1.030 20.580 0.772 1.507], , , , . In Fig. 6 the ( )Q V  spirometric test 
results have been added, for comparison.  
4.3 Statistical comparison of modelling results for microangiopathic and non- 
microangiopathic patients 
The mean parameter value and standard deviation were calculated separately for 
microangiopathic and non-microangiopathic patients (Table 5). The aim was to find out  
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Fig. 6. An example result of the spirometric measurement and modelling of the flow–
volume curve ( )Q V . 
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 
level p  
Mean model 
parameter 
Standard 
deviation 
Mean model 
parameter 
Standard 
deviation 
inA  5.92 1.72 5.88 2.20 0.05p   
  0.78 0.17 0.82 0.22 0.05p   
K  34.79 6.84 53.78 7.56 0.05p   
b  1.193 0.83 1.58 1.06 0.05p   
a  1.501 0.59 1.85 0.78 0.05p   
Table 5. Statistical comparison of model parameters for microangiopathic and non-
microangiopathic patients. For inA ,   and b , the ex post significance level was p  , 
0.05  , and thus the 0H , concerning mean parameter values equality, was not rejected – 
i.e. the parameters are not useful for diagnosis. However, parameters K  and a  are useful in 
distinguishing between patients with and without microangiopathy because the ex post 
significance level is p  , 0.05  . 
whether or not the model parameters are helpful in distinguishing between 
microangiopathic and non-microangiopathic patients. For this purpose the null hypothesis 
0
angiop non angiop
i iH p p
  , 1,..,5i   was tested. 
At first the normality hypothesis concerning the parameter estimates ip  was investigated, 
and the hypothesis was accepted (Kolmogorov-Smirnov test) at the significance level of 
0.05p  . Then the mean values and standard deviations (Table 5) were calculated and 
statistical test-T was performed. For K  and a  the ex post significance level p  , 0.05   
and 0H  is rejected. The two model parameters K  and a  allow for a distinction to be made 
between patients with and without microangiopathy.  
The remaining model parameters inA ,   and a  do not reveal the occurrence or absence of 
lung microangiopathy. 
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4.3 Binary classification on the basis of spirometric measurements and modelling 
Binary classification algorithms, based on the model parameters K  and a , were tested with 
discrimination levels KH  and aH . The discrimination levels were first established for all 
72M   subjects as 50.18KH   and 1.72aH  . These discrimination levels correspond to the 
K  and a  values for which maxSens Spec  . The 72M   subjects were now divided into 
two groups on the basis of these discrimination thresholds.  
Two algorithms, I and II (which gave the best results), were applied for binary classification. 
The algorithms are presented in Fig. 7. The binary classification decision was compared with 
previously known medical diagnoses, and then the Sens  and Spec  were calculated 
according to equations (8) and (9), (see Table 6).  
None of the tested algorithms could produce simultaneously a large Sens  and a large Spec . 
Algorithm II gave the best 82%Sens   and algorithm I gave the best 62%Spec  . Algorithm 
II accurately detected the majority of the microangiopathy cases ( 82%Sens  ), and only 
missed out on a few. Yet 50%Spec   means algorithm II identified only 50%  of the non-
microangiopathic patients as non-microangiopathic and gave too many false alarms. This is 
an unacceptable result. Somewhat better 62%Spec   was obtained with algorithm I but this 
was still not satisfactory. The most likely explanation for these poor results is the fact that 
the thresholds KH  and aH  are too general and do not take into consideration important 
anthropometric features. 
Therefore the range of anthropometric features was made more specific ( 1 22M   women, 
over 50 years old and under 1.65 m tall) and new diagnostic thresholds were calculated: 
48.11KH   and 1.68aH  . The new classification results are presented in Table 6. 
This more accurate choice of the diagnostic thresholds gave much better results. The 
100%Sens   means that algorithm II identified all the sick patients as sick. This excellent 
result has been obtained for the sample 1 22M   selected from the general population and 
therefore should be treated with care. An another sample may give a somewhat different 
result but the great improvement is obvious.  
The diagnostic procedure, utilising the algorithms I and II, is shown in Fig. 8.  
 
 
 
 
Fig. 7. Classification algorithms based on a  and K ; I) KM  are classified as 
microangiopathic and KM M  are classified as non-microangiopathic, II) a KM M  are 
classified as microangiopathic and ( )a KM M M   are classified as non-microangiopathic 
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Classification 
algorithm 
Full range of anthropometric 
features, 72M   (men and 
women, 21-69 y, 1.50-1.95m) 
Limited range of anthropometric 
features 1 22M  (women, over 50 
y, under 1.65 m) 
[%]Sens  [%]Spec  [%]Sens  [%]Spec  
I. ,a K  64 62 87 83 
II. ,K a  82 50 100 80 
Table 6. Classification results obtained for entire group of 72M   subjects and for the 
subgroup 1 22M   of women over 50 years old and under 1.65 m. The best results are 
underlined.  
 
Fig. 8. Classification algorithms: I) KM  are classified as microangiopathic and KM M  as 
non-microangiopathic, II) a KM M  are classified as microangiopathic and ( )a KM M M   
as non-microangiopathic 
Applied with aH  and KH , algorithm I gives the best (most conclusive) Sens  classification 
result, while the algorithm II gives the best (most conclusive) Spec  result.  
This procedure gives one of two alternative results: 1) high probability of lung 
microangiopathy or 2) high probability of no lung microangiopathy. The final decision is 
made by the doctor.  
5. Perfusion computed tomography (pCT)  
Tests commonly used in clinical practice such as spirometry and lung diffusion capacity 
measurements are not considered precise enough to identify lung microangiopathy. There 
are very few publications in this field and most of them concern the decrease of diffusion 
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capacity in diabetics (Villa et al, 2004), (Goldman, 2003). Autopsies of patients who died of 
diabetes complications revealed a thickening in the basement membrane of alveolar 
capillaries and arterioles in the lungs as well as of the entire walls of pulmonary arterioles 
together with fibroblast proliferation (Weynand et al, 1999).  
Impaired gas exchange in pulmonary alveoli results in the progressive reduction of reserves 
in small pulmonary vessels. For this reason lung perfusion in regions of lung 
microangiopathy may be diminished. Computed tomography of chest perfusion allows 
imaging of pulmonary vessels and parenchyma and may be useful in diagnosing 
pulmonary microangiopathy (Kuziemski et al, 2011).  
5.1 Patients and study protocol 
A group of 10 never-smoking diabetic adults and a control group of 8 non-diabetic 
volunteers were chosen. All participants had a similar body mass index and none of them 
suffered any disease that affected pulmonary function. The mean time from when diabetes 
mellitus was first diagnosed was 15.5 years. Nephropathy was diagnosed in 3 diabetics, 
retinopathy in 6 and polyneuropathy in 4. The question was whether or not they also 
suffered from lung microangiopathy. In the control group lung and cardio-vascular diseases 
were not diagnosed. 
For all patients, spirometry and diffusing capacity tests were performed.  
For the pCT tests a 64-row CT scanner GE - Light Speed VCT (GE Healthcare USA) was 
used. Pulmonary perfusion was evaluated after the intravenous administration of 40 ml of 
contrast at the rate of 4 ml/s. CT images were taken with 1 s resolution in the period of 40 s 
of a selected lung section (4 cm thick layer situated 2 cm below carina). Within this 4 cm 
thick segment, three cross-sections, anterior, medium and posterior, 5 mm thick each, were 
selected at uniform distances from each other. 6 ROIs were chosen in each of the cross-
sections (18 ROIs in all, numbered ROI 3-ROI 20). The ROIs 3–20 were situated in the upper, 
medial and lower parts of the left and right lungs. The most vascularised areas of the lungs 
were left beyond the ROIs so as not to distort the evaluation of lung parenchyma.  
The pCT measurements were performed using standard CT Perfusion 4 (GE Healthcare 
USA). The following perfusion parameters were  calculated: 
- [ 100 ]BV ml g  - blood volume in 100g of lung tissue. 
- [ /100 /min]BF ml g - blood flow through 100g of lung tissue in 1 minute. 
- [min]MTT - mean transit time through the vascular system in selected region. 
- [ /100 /min]PS ml g - permeability surface, the permeability of blood from intravascular 
to extravascular space, observed in 100g of lung tissue during 1 min. 
5.2 pCT results  
The example results of pCT scans, obtained from a 62 year old diabetic male, are shown in 
Fig. 9 a), b), c) and d). Perfusion parameters BF , BV , MTT  and PS  were calculated and 
mapped out on the lung cross-section. Analysis was made of the pulmonary artery - ROI 1, 
which represents the arterial input function, i.e. the flow blood into the pulmonary system.  
In Fig. 9 the ROI 1 is marked with a circle. The calculated values of perfusion parameters 
(mean value for all pixels in the region and standard deviation of the mean) are displayed in 
the right lower corner of the scan.  
Table 7 shows mean perfusion parameters Avg and standard deviation Dev in the ROI 1. 
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As the table shows, the obtained permeability surface PS for the impermeable pulmonary 
artery is equal to zero. The Dev, i.e. the disperse of parameter values within the ROI 1, is 
low, 4-7%. 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Fig. 9. The pCT scans (a) blood flow BF , (b) blood volume BV , (c) mean transit time MTT  
and (d) permeability surface PS  for a 62 year old diabetic male.  
 
Blood Flow 
BF 
Blood Volume 
BV 
Mean Transit Time 
MTT 
Permeability 
Surface PS 
Avg Dev Avg Dev Avg Dev Avg Dev 
509.9 20.64 48.06 3.48 5.65 0.30 0 0 
Table 7. Example results of perfusion parameters calculated as the mean values in the ROI 1 
marked in Fig. 9. The calculated standard deviations Dev illustrates the distribution of test 
results within ROI 1. 
(a) 
 
(b) 
 
Fig. 10. The PS maps  for (a) healthy subject and (b)  diabetic subject. For example, in ROI 13 
(right lower circle) 3.31PS   for the healthy subject and 79.80PS   for the diabetic subject. 
The measurements were obtained in the same location of the lung cross-section. 
Fig. 10 shows PS  maps obtained from a healthy patient and a diabetic patient. The 
qualitative comparison (amount of the red, permeable area) as well as the quantitative 
comparison (healthy patient 3.31PS   and diabetic patient 79.80PS  ) indicate damage to 
capillaries and pulmonary arterioles of the diabetic patient. 
All perfusion parameters were calculated in 18 ROIs (3-20) in the parenchyma to discover 
whether parameter values depend on the location of tested lung cross-section. Statistical 
analysis revealed no correlation between perfusion parameter value and ROI location in the 
upper central or lower part of the lungs (Kuziemski et al, 2011). Therefore mean perfusion 
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parameters were calculated for all 18 ROIs. The results are shown in Table 8 (Kuziemski et 
al, 2011). 
Here a noticeable increase was observed in the parenchyma perfusion parameter values of 
the diabetics with respect to control group, which may be due to diabetic mellitus.  
 
[ /100 /min]BF ml g Dev  [ /100 ]BV ml g Dev  [ /100 /min]PS ml g Dev  
Artery Parenchyma Artery Parenchyma Parenchyma 
Diabetes 
722.5301.8 
Diabetes 
282.2115.0 
Diabetes 
62.825.2 
Diabetes 
16.26.4 
Diabetes 
35.626.1 
Control 
681.7133.2 
Control 
207.653.4 
Control 
61.05.9 
Control 
12.01.8 
Control 
8.64.8 
Table 8. Mean parameters  BF , BV  and PS  in the artery and parenchyma of the diabetics 
and of the control group. The calculated standard deviation Dev illustrates the distribution 
of test results in 18 ROIs (ROI 3 – 20, in upper, central and lower part of lungs) with respect 
to the mean of the eighteen results. No significant MTT differences were found.  
Chest perfusion CT allows imaging of lung vessels and parenchyma, which is essential in 
diagnosing pulmonary angiopathy. The analyzed results are very new and currently not all 
that numerous. While this does not allow for a complex statistical analysis, the above 
preliminary results indicate the great potential of pCT tests in diagnosing lung 
microangiopathy. 
5.3 Lung area extraction  
Each pCT image (see Fig. 9) consists of the body cross-section, including the lungs, essential 
for medical diagnosis, the rest of the body and the background, which is unnecessary for 
lung diagnostics but was nevertheless included in the perfusion map calculations.  
As computations of perfusion parameters involve complicated methods of signal processing, it 
is desirable that the distinction between diagnostically important regions (the lung cross-
section) and other areas (background and the rest of body cross-section) is conducted before 
the process starts. This shortens the time needed to obtain parametric maps by omitting data 
processing from the area outside the lungs. It can also help avoiding false lung malfunction 
diagnoses, which can occur when the automatic methods of pathological changes wrongly 
interpret signals from areas outside the lungs as abnormal lung signals. 
Literature describes many methods of lung area extraction from CT chest scans (Homma et 
al, 2009), (de Nunzio et al, 2011), (Vinhais & Campilho, 2006), (Zhou et al, 2004). Most 
methods are devoted to extracting the lung area from a single image. Some of these methods 
allow for neighbouring (upper and lower) slices to be analysed (Homma et al, 2009). 
The lung extraction presented here was obtained using the two-step procedure. The 
objective of the preliminary processing was to define the rough mask, i.e. the border within 
which the lung contour is always contained during the pCT test while the lungs are 
breathing and the heart is beating. The lung and heart region contour pixels are subjected to 
the greatest changes. This behaviour can be utilised to detect the contours. It can be achieved 
by using a variability factor VF , which is defined as follows: 
 max min
median
x x
VF
x
  (14) 
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where maxx , minx  and medianx  are respectively each pixel’s maximum, minimum and 
median value. VF  can be used to create a variability map, VFM . Such a map is shown  in 
Fig. 11. 
 
 
Fig. 11. Map VFM  of variability factor VF . The white areas are the most variable due to the 
breathing lungs and beating heart. 
Then the final lung mask was obtained with the use of morphological operators (dilation, 
erosion, closing and opening) to extract lung cross-sections from the chest pCT.  
Fig. 12 shows the BF , BV , MTT  and PS  maps of just the lungs, extracted using the mask. 
The lung mask was superimposed onto the calculated maps in Fig. 9. 
 
(a) (b) (c) (d) 
Fig. 12. Lung extraction. The pCT lung maps obtained for the scans in Fig. 9 - (a) blood flow 
BF , (b) blood volume BV , (c) mean transit time MTT  and (d) permeability surface PS . 
Visual comparison of Fig. 9 and  Fig. 12 shows just how much unnecessary computations 
are usually performed in areas outside the lungs. What is more, a clearly defined lung area 
allows for a much more accurate and reliable medical diagnosis. 
6. Conclusion  
Pulmonary diabetic microangiopathy has not yet been sufficiently studied and is difficult to 
diagnose. In clinical practice, lung microangiopathy is diagnosed by comparing two 
diffusing capacity measurements, taken with the patient standing up and lying down. Other 
methods to assist diagnosis of lung microangiopathy are needed. 
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The three methods presented here seem good enough to be competitive options to 
complement those currently used in medicine today. 
Diffusing capacity measurement and modelling allows for the development of a procedure 
to enhance the diagnostic process. This procedure is based on a single diffusing capacity 
measurement taken from a patient lying down, together with a model of oxygen diffusion 
from the alveoli to the blood. The model parameters, calculated using routine medical test 
results and physiological constants,  turned out to be useful for binary classification in lung 
microangiopathy diagnosis. Diagnostic thresholds were calculated. Next binary 
classification was performed, based on model parameters, and, for comparison, on the 
diffusing capacity test result. These results were compared with already known medical 
diagnoses. This allowed for the sensitivity and specificity to be calculated. The best binary 
classification results were 79%Sens   and 87%Spec  , when based on model parameters, 
and, when based on diffusing capacity measurements, 62%Sens   and 71%Spec  . These 
results show that for microangiopathy diagnosis the model parameters were more sensitive 
and more specific than the diffusing capacity measurements.  
The next method to be  examined for usefulness in lung microangiopathy diagnosis was 
spirometry. Statistical comparison of the spirometry parameters of microangiopathic and 
non-microangiopathic patients, revealed that such parameters do not allow for a distinction 
to be made between patients with and without microangiopathy. Therefore a spirometry 
model was developed and its parameters were tested for their ability to distinguish between 
microangiopathic and non-microangiopathic subjects. Two, out of five, model parameters 
were statistically significant and helpful in lung microangiopathy diagnosis. Diagnostic 
thresholds were calculated and binary classification was performed, based on the 
statistically significant model parameters. The best results were 100%Sens   and 
83%Spec  . 
Both diagnostic procedures, the one based on the diffusing capacity and the one based on 
spirometric measurements and modelling, produce one of two possible results: 1) high 
probability of lung microangiopathy or 2) high probability of no lung microangiopathy.  
Perfusion CT measurement seems to have considerable diagnostic potential with regard to 
lung microangiopathy. A study of lung tissue perfusion in diabetic patients in comparison 
with a group of healthy subjects showed an increase in the value of some parameters. These 
increased values may result from pulmonary microangiopathy. Further studies on the 
application of pCT in the detection of diabetes mellitus may not only improve diagnosis but 
also help us better understand pulmonary microangiopathy. 
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